By Admin at 23 May 2016, 07:38 AM

As we mark the end of National Cancer Research Month, and prepare to celebrate National Cancer Survivors Day, we are highlighting recent immunotherapy breakthroughs that are saving lives of cancer patients TODAY!

• Longer term data has revealed more good news about Pembrolizumab, the immunotherapy drug that has been attributed to stopping Jimmy Carter’s cancer, offering melanoma patients new hope.
  
  
• Immunotherapy research advances are paving the way for longer survival rates for lung and advanced blood cancers.
  
  
• The recent 60 Minutes report on the use of the polio vaccine to stop Glioblastoma, one of the deadliest forms of brain cancer, is one promising example of how researchers are using virus based drugs to wage war on cancer cells.

Many of these new immunotherapy discoveries are only made possible via Phase I and II clinical trials – the very type of clinical trials Gateway funds. While the most underfunded, these human trials offer the most hope for patients to feel better, live longer and conquer cancer TODAY!

Now, thanks to our generous donors, Gateway has just approved two new immunotherapy trials:

• A brain cancer study at MD Anderson will assess if immunotherapy can target a virus (cytomegalovirus or CMV) that is commonly found in Glioblastoma cancer cells but not in normal brain tissue.
  
  
• A pancreatic cancer study at Johns Hopkins will assess the effectiveness of combining five treatment modalities (including the promising new drug Pembrolizumab) on patients with aggressive and deadly advanced pancreatic adenocarcinoma.

The addition of these ground-breaking trials brings the number of active Gateway-funded human clinical trials to an all-time high of 55!  As we approach what could be the tipping point in the war against cancer, we must do more! And with your help, we can. Help us celebrate National Cancer Survivors Day by providing real hope to a cancer patient TODAY! Please donate now.

At Age 17, Maddy Oliver was diagnosed with osteosarcoma, an aggressive bone
malignancy with one of the lowest survival rates for pediatric cancer. Watch Maddy's
update one and a half years after completion of her Gateway-funded clinical trial.

Post a comment

Make me anonymous

CAPTCHA
Below question is to prevent automated spam submissions.

* Math Question:

2 + 1 =

Solve this math problem and enter the result. E.g. for 1 + 3, enter 4.

You must provide a response to the reCaptcha challenge.